Inventera인벤테라

Inventera is a pre-revenue Korean nanomedicine developer with large losses, a share price that has swung sharply, and a targeted turn to profit in 2028.

Inventera reported no revenue in the trailing twelve months to H1 2026 and an operating loss of about ₩8.6B, with free cash flow of about -₩6.5B. Its cash of about ₩1.4B against borrowings of about ₩0.6B is small relative to those losses, and the data does not show how the gap will be funded. The company is developing nano-MRI contrast agents, with its lead candidate in Phase 3 in Korea.

What stands out

• No revenue is reported in the data; the 2025 annual figures and H1 2026 trailing figures both show zero sales.
• Operating loss of about ₩8.6B and net loss of about ₩8.0B over the trailing period; return on equity is -26.9%.
• The share price closed at ₩8,750, down 38.4% over one month but up 18.6% over three months, within a 52-week range of ₩6,090 to ₩60,200.
• Recent news reports a U.S. Phase 1 approval for an oral pancreaticobiliary contrast agent and a plan to file for approval of INV-002 in Q4, with a target of profit in 2028.
• Valuation fields show a price-to-book of 2.3 and no earnings-based multiples, since earnings are negative; the company pays no dividend.

What to watch

• The planned Q4 2026 approval filing for the musculoskeletal MRI contrast agent, as described in news reports rather than a filing in the data.
• The next half-year or quarterly reports, to see whether losses and cash burn change and whether any new funding is disclosed.
• Recent 'major management matter' filings and a stock purchase option grant, the reasons for which are not stated in the data; foreign ownership fell from 4.8% to 1.6% over about 60 days.